OSTEOARTHRITIS
Tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee
This report has been verified
by one or more authors of the
original publication.
Osteoarthritis Cartilage; 2011;19(12):1405-1412
83 Japanese patients with moderate to severe osteoarthritis of the knee were randomized to receive either tanezumab 10, 25, 50, 100 or 200 mg/kg or a placebo. The results from 120 day follow-up indicated that stronger doses of tanezumab result in significantly better pain relief in comparison to baseline measurements. However, the results from the study also indicated that adverse events occurred in 6 patients who received the drug in comparison to 1 who received placebo.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
